好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Transcranial Direct Current Stimulation for Developmental Dyslexia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Child Neurology and Developmental Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
8-001

To assess the efficacy and safety of transcranial direct current stimulation (tDCS) in improving pseudoword reading performance and associated outcomes in individuals with developmental dyslexia in comparison to sham.


Developmental dyslexia impacts 5 to 10% of children globally and is marked by diminished activation in left-hemisphere reading circuits. tDCS has surfaced as a possible complement to behavioural therapies; nonetheless, variable stimulation regimens and small, heterogeneous trials have constrained definitive findings about its clinical efficacy.
We searched seven databases (PubMed, Embase, Scopus, ClinicalTrials.gov, PsycINFO) from inception to October 2025 for RCTs of tDCS on dyslexia. The primary outcome was pseudoword reading. Additional outcomes were word reading, fluency, phonological and cognitive measures, long-term retention, and side effects. The pooled SMD or MD with 95% CI were calculated by random-effects models.

Ten RCTs (249 patients;125 underwent active tDCS) were identified. Active tDCS produced a significant improvement in rapid automatized naming–letters (MD = −1.08;95% CI−2.04 to−0.11;p=0.03; I²=20%). Long-term pseudoword retention favor active tDCS (SMD=0.62;95 %CI 0.05 to 1.19;p=0.03;I²= 50%), along with low-frequency word accuracy (MD =0.49;95% CI, 0.03 to 0.95;p =0.04;I² =46%).No significant differences were found for pseudoword reading accuracy (SMD =0.32;95% CI −0.08 to 0.72;p=0.11;I² =0%), speed (SMD =0.10;95% CI−0.27 to 0.47; =0.60;I² =0%), fluency - text (SMD =−0.01;95% CI−0.54 to 0.51;p =0.96;I²=0%), low-frequency (MD =0.59;95% CI−6.12 to 7.31;p =0.86;I²=0%) and high-frequency (MD =−0.34;95% CI−4.20 to 3.53;p =0.86;I²=0%) or phonological awareness, including phoneme blending accuracy (MD=0.02;95% CI−1.26 to 1.21;p=0.97;I²=0%) and phoneme blending time (MD=−2.04;95% CI−9.85 to 5.77;p=0.67;I² = 0%). Total adverse event risk was higher with sham (RR=2.08;95% CI 1.28–3.38;p=0.003;I²=0%).


tDCS did not significantly improve reading outcomes in comparison to sham in developmental dyslexia. However, small benefits were seen in rapid naming tasks. The current evidence does not support routine clinical use. Larger trials are needed to determine its role as an adjunct therapy.


Authors/Disclosures
Dhyey Sidhpura, MD
PRESENTER
Dr. Sidhpura has nothing to disclose.
Amna Hussain, MBBS Miss Hussain has nothing to disclose.
Abdur Rehman, MBBS Dr. Rehman has nothing to disclose.
Mohammad Daniyal, Jr., MBBS Dr. Daniyal has nothing to disclose.
Talha Ali, MBBS Dr. Ali has nothing to disclose.
Rahma naveed, MBBS Ms. naveed has nothing to disclose.
Muhammad H. Khattak Dr. Khattak has nothing to disclose.
Sarah Azhar, MBBS Miss Azhar has nothing to disclose.
Huzaifa S. Nawaz, MBBS Dr. Nawaz has nothing to disclose.
Syeda Ramish Z. Kazmi, MBBS Miss Kazmi has nothing to disclose.
Safa Shahid, MBBS Miss Shahid has nothing to disclose.
Aisha Rizwan Ahmed, MBBS Dr. Rizwan Ahmed has nothing to disclose.